諾輝健康-B(06606.HK)香港公開發售獲4133.19倍認購 上限定價26.66港元/股
格隆匯 2 月 17日丨諾輝健康-B(06606.HK)發佈公吿，公司全球發售7659.8萬股股份，其中香港發售股份3829.9萬股，國際發售股份3829.9萬股，另有15%超額配股權；發售價已釐定為每股發售股份26.66港元，每手買賣單位500股；高盛及UBS為聯席保薦人，預期股份將於2021年2月18日於聯交所主板掛牌上市。
國際發售初步提呈發售的發售股份獲大幅超額認購，相當於國際發售初步可供認購發售股份總數約64.16倍。根據香港公開發售初步提呈發售的香港發售股份獲非常大幅超額認購。公司合共接獲1,063,663份有效申請，認購合共316.6億股，相當於香港公開發售初步可供認購香港發售股份總數約4,133.19倍。
根據發售價每股發售股份26.66港元及根據相關基石投資協議，基石投資者認購合共3606.25萬股發售股份，相當於公司緊隨全球發售完成後已發行股本約8.63%(假設概無因行使首次公開發售前股權激勵計劃下的購股權而發行額外股份)；及全球發售項下發售股份數目的47.08%(在各情況下均假設並無行使超額配股權)。
按發售價每股發售股份26.66港元計算，公司估計自全球發售收取所得款項淨額約18.986億港元。其中，所得款項淨額約40%將分配用於為常衞清(作為醫療服務或獨立產品)的商業化及進一步開發提供資金；約5%將分配用於通過提高結直腸癌篩查意識及提升市場滲透率為噗噗管的持續銷售及營銷提供資金，並在不同人羣中進行更多噗噗管的臨牀評估；約30%將分配用於為正在進行及計劃進行的研發提供資金以進一步發展幽幽管、宮證清及其他處於早期階段的管線產品；約15%將用於通過潛在收購或外部引進癌症篩查領域的候選產品持續擴大及多元化公司的產品組合；及約10%將用作公司的營運資金及其他一般企業用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
